China’s yuan traded past ¥7 per dollar on Thursday for the first time in over a year, with the offshore unit reaching 6.9964 and onshore settling at 7.0067, accordingChina’s yuan traded past ¥7 per dollar on Thursday for the first time in over a year, with the offshore unit reaching 6.9964 and onshore settling at 7.0067, according

Yuan breaks ¥7 per dollar level for the first time since September 2024

2025/12/25 22:15
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

China’s yuan traded past ¥7 per dollar on Thursday for the first time in over a year, with the offshore unit reaching 6.9964 and onshore settling at 7.0067, according to data from Google Finance.

The rally comes after a firmer daily reference rate set by the People’s Bank of China, which market desks read as another step in a pattern seen over recent months, with policymakers allowing gains at a measured pace while keeping tight control over daily swings.

Central bank allows gains as dollar selling builds in local markets

The yuan has surged by more than 3.8% this year, helped by a weaker US dollar, money flowing into China’s stock market rebound, and easing global tensions.

“The yuan has been bolstered by weakness in the dollar and seasonal foreign-exchange conversion by exporters,” said Wang Qing, chief macro analyst at Golden Credit Rating. “A sustained yuan gain will be helpful in increasing the appeal of China’s capital markets to foreign investors.”

Onshore markets saw active dollar selling during Thursday’s session, as traders allegedly said large Chinese banks were buying dollars around 7.006.

Offshore trading remained thin as well. Hong Kong markets were closed on Dec. 25 and Dec. 26 for public holidays, which limited liquidity during the session, traders said.

Despite the rally, some banks say the yuan still trades at low levels when compared with trade partners and domestic conditions.

Goldman Sachs Group Inc. said the currency stood about 25% below levels suggested by economic fundamentals, including China’s ongoing deflation pressures.

Zhaopeng Xing, senior strategist at Australia & New Zealand Banking Group, said the yuan is likely to stay in a 6.95 to 7 per dollar range during the first half of next year.

Property debt talks resume as Vanke bond vote reaches deadline

Currency strength has unfolded alongside renewed pressure in China’s property sector. China Vanke Co., which recently secured temporary relief on a local bond, returned to negotiations as holders of another note finished voting on a payment delay.

Investors holding a 3.7 billion yuan bond, worth about $526 million, were given until 3 p.m. Thursday to choose from six proposals seeking to push back repayment. Without approval, the developer would need to pay the bond when it falls due on Dec. 28, or within a five working day grace period, raising the risk of default.

Vanke carries about $50 billion in interest-bearing liabilities as the housing market continues to struggle with falling prices and weak demand. The latest talks followed a narrow vote that extended a grace period on a 2 billion yuan bond, even as a proposal to delay principal repayment by 12 months failed.

This week, S&P Global Ratings cut Vanke’s long-term issuer rating to selective default, saying the grace-period extension counted as a distressed debt restructuring.

Some offshore bondholders have been contacted by Houlihan Lokey Inc. and PJT Partners, firms often involved before formal creditor groups are set up to handle restructuring talks.

At the policy level, officials continue to adjust housing rules while avoiding direct rescues of individual firms.

Beijing city said it will ease home purchase rules for non-residents to support sales. The capital will cut the number of years buyers must have paid income tax or social security before they can buy a home, based on a Wednesday announcement.

Get $50 free to trade crypto when you sign up to Bybit now

Market Opportunity
ConstitutionDAO Logo
ConstitutionDAO Price(PEOPLE)
$0.006892
$0.006892$0.006892
-2.17%
USD
ConstitutionDAO (PEOPLE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09